sugemalimab
Cejemly (sugemalimab) is a PD-L1 checkpoint inhibitor from CStone Pharmaceuticals approved in the European Union for non-small cell lung cancer. With platinum-based chemotherapy it is a first-line treatment of metastatic disease, and as monotherapy it treats unresectable stage III disease after chemoradiotherapy.
This page is based on the EMA medicine record for sugemalimab, cross-checked with the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
A lung tumour raises a PD-L1 white flag that presses the PD-1 brake on passing T cells, so the immune patrol stands down. Sugemalimab paints over the flag. The patrol can no longer read the surrender signal, sees the tumour clearly, and attacks alongside chemotherapy or on its own after chemoradiation.
In simple terms
Sugemalimab is a fully human antibody given by infusion that binds PD-L1, a protein many cancer cells display to switch off attacking T cells. By blocking PD-L1, sugemalimab prevents it from engaging the PD-1 off-switch, reversing T-cell inactivation and enhancing the cytotoxic T-cell response against tumour cells. It is used in the European Union with platinum-based chemotherapy for first-line metastatic non-small cell lung cancer and alone for unresectable stage III disease that has not progressed after chemoradiotherapy.
In depth
Sugemalimab (CS1001) is a fully human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1, CD274). Upon administration it specifically targets and binds PD-L1, blocking its binding to and activation of its receptor PD-1, which reverses T-cell inactivation caused by PD-1/PD-L1 signalling and enhances cytotoxic T-lymphocyte-mediated anti-tumour immune responses against PD-L1-expressing tumour cells. The antibody mirrors natural immunoglobulin G4 (IgG4), potentially reducing immunogenicity and other toxicities.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How sugemalimab, a fully human anti-PD-L1 antibody, restores the T-cell attack
- Sugemalimab (CS1001) is a fully human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1, CD274).
- Upon administration it specifically targets and binds PD-L1, blocking its binding to and activation of its receptor PD-1, which reverses T-cell inactivation caused by PD-1/PD-L1 signalling and enhances cytotoxic T-lymphocyte-mediated anti-tumour immune responses against PD-L1-expressing tumour cells.
- The antibody mirrors natural immunoglobulin G4 (IgG4), potentially reducing immunogenicity and other toxicities.
- It is used in the European Union with platinum-based chemotherapy for first-line metastatic non-small cell lung cancer and alone for unresectable stage III disease that has not progressed after chemoradiotherapy.
Target: Programmed death-ligand 1 (PD-L1)
An immunosuppressive ligand overexpressed by many cancers; binding PD-1 on T cells it switches them off, so blocking PD-L1 restores the cytotoxic T-cell attack against the tumour.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in European Union
EMA- In combination with platinum-based chemotherapy, for the first-line treatment of adults with metastatic non-small cell lung cancer with no sensitising EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations
- As monotherapy, for the treatment of adults with unresectable stage III non-small cell lung cancer with no sensitising EGFR mutations, or ALK, ROS1 genomic tumour aberrations, whose tumours express PD-L1 on 1 percent or more of tumour cells and whose disease has not progressed following platinum-based chemoradiotherapy
Official sources
The statements on this page trace back to these records.
- Cejemly (sugemalimab) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- National Cancer Institute: sugemalimab
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.